Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Blistering skin diseases can range from relatively mild to extremely painful and debilitating. Both genetic (inherited/Epidermolysis Bullosa) as well as acquired (autoimmune/Pemphigus/Pemphigoid ) forms of blistering can occur. Precise diagnosis of these diseases is extremely important and therapy of blistering diseases can be challenging, requiring a familiarity with medicines which are only infrequently used by many dermatologists.
Our clinic works closely with the Stanford Dermatopathology Department to provide advanced diagnostic services for autoimmune bullous disease, including direct and indirect immunoflorescence microscopy and salt split skin analysis.
In addition to standard immune based therapies, we also provide:
Many of these services are available for administration in our immediately adjacent Infusion Center in the Stanford Redwood City Medical Outpatient Center.
Inherited Epidermolysis Bullosa
Our clinic works closely with the Stanford Dermatopathology Department to provide advanced diagnostic services for epidermolysis bullosa including electron microscopy and direct immunofluorescence microscopy, and with GeneDx to provide DNA analysis.
While this clinic is devoted to the care of adult EB patients, we work in close association with the Epidermolysis Bullosa Clinic at Lucile Packard Children’s Hospital led by a group of pediatric trained physicians and nurses that care for children with epidermolysis bullosa. Epidermolysis bullosa therapy at Stanford adopts a multidisciplinary approach, enlisting help as needed from a team of collaborative specialists from other disciplines including Nutrition, Genetics, Oral Medicine, Dermatologic and Plastic Surgery, Otolaryngology, Urology, Infectious Diseases, Psychiatry, Gastroenterology and Physical Therapy.
Together we can provide care for the full array of problems affecting epidermolysis bullosa patients including:
Supportive wound care
Treatment of infections
Diagnosis and treatment of skin cancers
Treatment of oral, espophageal, laryngeal, rectal and genitourinary disease
In addition to these standard therapies, Stanford is actively performing research to develop new protein, gene and cell based therapies for epidermolysis bullosa as seen in the clinical trials section below.
For more information about our epidermolysis bullosa research program, please contact
Linette Jimenez, firstname.lastname@example.org.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
When you refer one of your patients to a Stanford Health Care’s Dermatology Clinic, we want to assure you that we’ll provide him or her with the same level of personal care you give them.
HOW TO REFER
To refer a new patient, fax the patient referral form with any supporting documentation to 650-721-3476. A Patient Care Coordinator will fax a confirmation of receipt to your office. We will contact the patient and schedule an evaluation appointment upon insurance clearance.